AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Modalis Therapeutics Corporation

¥32 -$26.00 (-44.83%)
JPX · 15 Sep 2026 06:30 UTC
Previous Close
¥33
Day Range
¥32¥34
Year Range
¥29¥84
Market Cap
3.08B
AVG Volume
1.9M
Trailing/Forward PE
-1.33/-
PEG ratio
-0
Dividend Yield
-
Next Earnings Date
2026-11-11
Primary Exchange
Tokyo Stock ExchangeJP
Net Income (JPY)
-3B-2B-1B02022202320242025
4883.T Net Income (JPY) by year
PeriodNet Income (JPY)
2025-2.15B
2024-1.32B
2023-2.39B
2022-1.93B
Operating Income (JPY)
-3B-2B-1B02022202320242025
4883.T Operating Income (JPY) by year
PeriodOperating Income (JPY)
2025-2.21B
2024-1.34B
2023-2.37B
2022-1.19B
EBITDA (JPY)
-3B-2B-1B02022202320242025
4883.T EBITDA (JPY) by year
PeriodEBITDA (JPY)
2025-2.19B
2024-2.09B
2023-2.39B
2022-1.86B
Cash Flows (JPY)
-10M-5M05M10M2022202320242025
4883.T Cash Flows (JPY) by year
PeriodCash Flows (JPY)
2025-6.94M
20245.07M
20230
20220
EPS (JPY)
-80-60-40-2002022202320242025
4883.T EPS (JPY) by year
PeriodEPS (JPY)
2025-28.18
2024-33.67
2023-77.65
2022-66.06
Expenses (JPY)
01B2B3BR&DSG&A2022202320242025
4883.T Expenses (JPY) by year
PeriodExpenses (JPY)
20252.21B
20242.12B
20232.37B
20221.13B
Cash & Debt (JPY)
02B4B6BCashLong Term Debt202020212022202320242025
4883.T Cash & Debt (JPY) by year
PeriodCash & Debt (JPY)
20252.81B
20243.58B
20231.88B
20222.93B
20214.94B
20205.42B
Debt ratios
00.511.52025
4883.T Debt ratios by year
PeriodDebt ratios
20250.33
Return on Capital
-200%-150%-100%-50%0%2022202320242025
4883.T Return on Capital by year
PeriodReturn on Capital
2025-77.07%
2024-37.14%
2023-173.27%
2022-65.57%
Shares Outstanding
025M50M75M100M2022202320242025
4883.T Shares Outstanding by year
PeriodShares Outstanding
202588.96M
202445.99M
202331.92M
202229.19M
Book Value Per Share (JPY)
0501001502022202320242025
4883.T Book Value Per Share (JPY) by year
PeriodBook Value Per Share (JPY)
202531.4
202477.16
202343.25
2022100.69
Total Assets (JPY)
02B4B6B8B202020212022202320242025
4883.T Total Assets (JPY) by year
PeriodTotal Assets (JPY)
20252.96B
20243.69B
20232.03B
20223.13B
20216.07B
20206.28B
Price to Book
012345med 1.67Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
4883.T Price to Book by year
PeriodPrice to Book
Sep 261.05
Sep 261.14
Sep 261.11
Aug 261.05
Aug 261.05
Aug 261.05
Aug 261.02
Jul 260.95
Jul 261.02
Jul 261.05
Jul 261.05
Jul 261.05
Jun 260.96
Jun 261.05
Jun 261.08
Jun 261.24
May 261.43
May 261.88
May 262.04
May 262.17
May 262.1
Apr 261.88
Apr 261.72
Apr 261.72
Apr 261.82
Mar 261.66
Mar 261.66
Mar 261.66
Mar 261.69
Feb 261.69
Feb 261.63
Feb 261.63
Feb 261.66
Jan 261.72
Jan 261.8
Jan 261.86
Jan 261.75
Dec 251.6
Dec 251.27
Dec 251.18
Dec 251.32
Dec 251.43
Nov 251.54
Nov 251.5
Nov 251.59
Nov 251.61
Oct 251.72
Oct 251.77
Oct 251.75
Oct 251.79
Oct 251.77
Sep 251.79
Sep 251.77
Sep 251.75
Sep 251.94
Aug 251.97
Aug 251.9
Aug 251.94
Aug 251.88
Aug 251.99
Jul 251.97
Jul 251.97
Jul 252.05
Jul 251.77
Jun 251.09
Jun 251.1
Jun 251.14
Jun 250.99
May 250.99
May 250.99
May 251.06
May 250.95
May 250.97
Apr 251
Apr 251.05
Apr 251
Apr 251.01
Mar 251.64
Mar 251.66
Mar 251.61
Mar 251.57
Feb 251.59
Feb 251.81
Feb 251.82
Feb 251.79
Jan 251.75
Jan 251.86
Jan 251.82
Jan 251.9
Dec 241.86
Dec 243.52
Dec 243.45
Dec 243.83
Dec 244
Nov 244.66
Nov 244.87
Nov 244.28
Nov 243.93
Nov 244.56
Oct 244.07
Modalis Therapeutics Corporation
4883.T
Stockpicker

Video analysis: 4883.T

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.